What’s Going On With SoFi Technologies Stock?

SoFi Technologies, Inc. (NASDAQ: SOFI) shares are trading lower Thursday.

SoFi Technologies, Inc. (NASDAQ:SOFI) shares are trading lower Thursday. The stock appears to be moving on continued downward momentum from the last five days.

What To Know:

SoFi Technologies shares are down more than 15% over the last five days and several company insiders have sold large amounts of SoFi stock.

A Form 4 filing from the U.S. Securities and Exchange Commission showed that Aaron Webster, Sofi’s chief risk officer, sold 215,299 SOFI shares on Nov. 3. The total transaction amounted to $1,740,541.

On Nov. 6, Sofi’s chief marketing officer Lauren Stafford sold 135,832 SOFI shares in a transaction totaling $1,029,096, and Chad Borton, president of SoFi, sold 152,041 SOFI shares in a transaction totaling $1,215,817 on Nov. 2.

CNBC’s Jim Cramer recently recommended buying SoFi Technologies’ stock saying, “They are turning the corner, and they are doing everything right. I think it goes higher.”

Shares of SOFI are dropping on heavy trading volume Thursday. According to data from Benzinga Pro, more than 40 million shares have been traded in the session, compared to the stock’s 100-day average of 28.685 million shares.

Related News: What’s Going On With MicroStrategy Incorporated Stock?

SOFI Price Action: According to Benzinga Pro, SoFi Technologies shares are down 6% at $6.87 at the time of publication.

Image: Foto-RaBe from Pixabay

Total
0
Shares
Related Posts
Read More

Honda’s Bet On Canadian EV Hub: Reportedly Plans $11B Investment

Honda Motor reportedly announces a groundbreaking $11 billion investment to pioneer electric vehicle manufacturing in Canada. Collaborating with Canadian authorities, this strategic move signifies Honda's commitment to meeting the rising demand for electric vehicles in North America. The decision underscores a significant milestone for Canada's emergence as a pivotal player in the regional electric vehicle market.

AVDE

Read More

Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment well tolerated with no serious adverse events

ACHV